GlaxoSmithKline Pharmaceuticals net sales up 12% in third quarter of FY 2009

Businesswire India
Posted: Friday, Oct 30, 2009 at 1424 hrs IST
Updated: Friday, Oct 30, 2009 at 1424 hrs IST

Font Size

Feedback

Discuss

Biotracker LIMS receives caBIG bronze compatibilit...Virtusa wins Information Management’s Innovative S...Indusface winner in the Deloitte's technology Fast...Wipro Technologies creates job opportunities in At...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2009.

The Company posted Net Sales growth of 12% compared to the previous quarter, while Profit before Investment Income and Taxes grew by 13% on a comparable basis.

Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, “Sales during the quarter have shown growth across mass, mass speciality, vaccines and speciality therapies. Recent launches of Tykerb for refractory breast cancer, Benitec an anti-hypertensive drug from Daiichi Sankyo and Cervarix for cervical cancer are making steady progress. Vaccines have recorded strong growth with the rotaviral diarrhea vaccine tracking ahead of plan".

More from Business Wire

Viola Systems Launches Arctic Control to Tackle Power Outages ESOP Direct and 9.9 Media Host Conference on “Aligning Interests of Management and Employees” Avaya GlobalConnect Reports Buoyant Results for Q4 09 Biotracker LIMS receives caBIG bronze compatibility certification Virtusa wins Information Management’s Innovative Solution award Indusface winner in the Deloitte's technology Fast 50 India program Acute coal shortage to push up import Wipro Technologies creates job opportunities in Atlanta

Discuss this story on expressindia forums

Post Comments

Comments: (Limit 3,000 characters)

Name		Message
Email ID
Subject

TERMS OF USE:
The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).

I agree to the terms of use.

Latest News

Print Edition

Events

GlaxoSmithKline Pharmaceuticals net sales up 12% in third quarter of FY 2009

Post Comments